Arbutus Biopharma Corporation Common Stock (NASDAQ:ABUS)

Home >> Stock >> Arbutus Biopharma Corporation Common Stock >> Reports

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC....

+See More
See More

Blog+More

Netflix suffers its first major loss of U.S. subscribers due to the recent price hikes.

Rose Prince

2019-08-14 10:31:00 Wednesday ET

Netflix suffers its first major loss of U.S. subscribers due to the recent price hikes.

Netflix suffers its first major loss of U.S. subscribers due to the recent price hikes. The company adds only 2.7 million new subscribers in 2019Q2 in stark

+See More

Timothy Geithner shares his reflections on the post-crisis macro financial stress tests for U.S. banks.

Fiona Sydney

2023-04-07 12:29:00 Friday ET

Timothy Geithner shares his reflections on the post-crisis macro financial stress tests for U.S. banks.

Timothy Geithner shares his reflections on the post-crisis macro financial stress tests for U.S. banks. Timothy Geithner (2014)   Macrofinanci

+See More

MIT financial economist Simon Johnson rethinks capitalism with better key market incentives.

Daisy Harvey

2019-11-23 08:33:00 Saturday ET

MIT financial economist Simon Johnson rethinks capitalism with better key market incentives.

MIT financial economist Simon Johnson rethinks capitalism with better key market incentives. Johnson refers to the recent Business Roundtable CEO statement

+See More

U.S. tech titans increasingly hire PhD economists to help solve business problems.

Monica McNeil

2019-03-19 12:35:00 Tuesday ET

U.S. tech titans increasingly hire PhD economists to help solve business problems.

U.S. tech titans increasingly hire PhD economists to help solve business problems. These key tech titans include Facebook, Amazon, Microsoft, Google, Apple,

+See More

Several feasible near-term reforms can substantially narrow the scope for global tax avoidance by closing information loopholes.

Apple Boston

2023-03-14 16:43:00 Tuesday ET

Several feasible near-term reforms can substantially narrow the scope for global tax avoidance by closing information loopholes.

Several feasible near-term reforms can substantially narrow the scope for global tax avoidance by closing information loopholes. Thomas Pogge and Krishen

+See More

What are the primary pros and cons of free trade or fair trade in the current Sino-American quagmire?

Jonah Whanau

2018-05-02 06:32:00 Wednesday ET

What are the primary pros and cons of free trade or fair trade in the current Sino-American quagmire?

What are the primary pros and cons of free trade or fair trade in the current Sino-American quagmire? Free trade means allowing goods and services to move a

+See More